Brokerages Set Ambrx Biopharma Inc. (NYSE:AMAM) Target Price at $19.80

Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) has received an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price […]

Related Keywords

Canada ,Ambrx Biopharma ,Ambrx Biopharma Inc ,Ghost Tree Capital ,Ambrx Biopharma Company Profile ,Farallon Capital Management ,Cantor Fitzgerald ,Pricet Rowe Associates Inc ,Royal Bank ,Darwin Global Management Ltd ,Get Free Report ,Marketbeat Ratings ,Global Management ,Capital Management ,Tree Capital ,Pricet Rowe Associates ,Biopharma Trading Down ,Get Free ,Biopharma Inc ,Ambrx Biopharma Daily ,Nyse Amam ,Hamam ,Medical ,Ratings ,Consensus ,